RaQualia Pharma Inc. ( (JP:4579) ) has shared an update.
RaQualia Pharma Inc. reported a significant increase in net sales for the fiscal year ending December 31, 2024, with a 63.5% rise compared to the previous year, despite reporting a loss in operating and ordinary profits. The company also highlighted the inclusion of FIMECS, Inc. in its scope of consolidation, marking a strategic expansion. Although financial challenges persist, the company forecasts a positive outlook for 2025 with expected increases in net sales and operating profit.
More about RaQualia Pharma Inc.
RaQualia Pharma Inc. is a pharmaceutical company listed on the Tokyo Stock Exchange, focusing on developing and marketing pharmaceutical products.
YTD Price Performance: 6.77%
Average Trading Volume: 99,266
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen8.95B
For detailed information about 4579 stock, go to TipRanks’ Stock Analysis page.